Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 341Ovarian Neoplasms 177Lung Neoplasms 171Breast Neoplasms 118Fallopian Tube Neoplasms 87Neoplasms 79Carcinoma, Ovarian Epithelial 69Squamous Cell Carcinoma of Head and Neck 51Small Cell Lung Carcinoma 49Triple Negative Breast Neoplasms 41Adenocarcinoma of Lung 41Head and Neck Neoplasms 40Neoplasm Metastasis 37Neuroblastoma 34Central Nervous System Neoplasms 33Endometrial Neoplasms 28Esophageal Neoplasms 27Carcinoma 27Brain Neoplasms 27Lymphoma 26Recurrence 25Lymphoma, Large B-Cell, Diffuse 25Urinary Bladder Neoplasms 24Parkinson Disease 4, Autosomal Dominant Lewy Body 24Adenocarcinoma, Bronchiolo-Alveolar 23Testicular Neoplasms 22Astrocytoma 22Melanoma 19Uterine Cervical Neoplasms 18Prostatic Neoplasms 18

Interventions

trametinib 1dabrafenib 1Vincristine 1Irinotecan 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroma × Carboplatin × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡